# Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma

> **NCT00635323** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 73 (estimated)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Irinotecan plus capecitabine

## Key facts

- **NCT ID:** NCT00635323
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-11
- **Primary completion:** —
- **Final completion:** 2005-05
- **Target enrollment:** 73 (ESTIMATED)
- **Last updated:** 2008-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635323, "Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00635323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*